Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
[This corrects the article DOI: 10.1371/journal.pone.0222259.].
Main Authors: | Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0253671 |
Similar Items
-
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
by: Gianluigi Giannelli, et al.
Published: (2020-01-01) -
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
by: PLOS ONE Staff
Published: (2020-01-01) -
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
by: James J. Harding, et al.
Published: (2021-05-01) -
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
by: Herbertz S, et al.
Published: (2015-08-01) -
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
by: Rikke B. Holmgaard, et al.
Published: (2018-06-01)